ArticleScientific reports2026
Computational stability analysis suggests binding-independent destabilization in pathogenic FBXO11 variants.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
FBXO11 binds SKP1 within an SCF E3 ubiquitin ligase complex, where it recognizes substrates for ubiquitination and degradation. Pathogenic FBXO11 variants cause neurodevelopmental disorders, yet several retain normal SKP1 binding, indicating that disrupted SKP1 binding alone cannot account for disease. We integrated multi-conformational AlphaFold3 models with FoldX and Rosetta stability predictions to evaluate 44 missense variants (23 pathogenic, 21 benign). Pathogenic variants showed greater predicted destabilization than benign controls by both methods (FoldX 1.86 vs. 0.54 kcal/mol, Cohen's d = 0.50; Rosetta 6.85 vs. 1.31 kcal/mol, Cohen's d = 0.78; both p < 0.01, FDR-corrected). Discrimination was consistent in both the FBXO11 monomer and the FBXO11-SKP1 complex contexts. Among ten pathogenic variants with experimentally validated normal SKP1 binding, 9/10 by FoldX and 8/10 by Rosetta exceeded a 1.0 kcal/mol threshold (10/10 by either method). Benchmarking against AlphaMissense, REVEL, and CADD indicated that physics-based ΔΔG provides complementary mechanistic information to existing predictors. Exploratory molecular dynamics simulations (300 ns total) suggested elevated backbone RMSD in pathogenic variants. These findings support a hypothesis of binding-independent destabilization in FBXO11-associated pathogenesis, although requiring further computational analysis and experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.